JNJ Stock Recent News

Johnson & Johnson (NYSE:JNJ) reported better-than-expected first quarter profits driven by strong sales of its cancer drugs, but shares of the pharma giant traded lower as revenue narrowly missed estimates. For Q1, the company reported that its adjusted earnings per share (EPS) increased by 12.4% to $2.71, topping estimates of $2.64.

The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Johnson & Johnson (JNJ) posted a mixed first-quarter earnings Tuesday, and raised its dividend while narrowing full-year guidance for 2024.

Shares of Johnson & Johnson NYSE: JNJ are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face.

A senior official at Nigeria's drug regulator said on Tuesday that the regulator had no record of children dying from a batch of cough syrup manufactured by Johnson & Johnson which had been recalled.

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.68 per share a year ago.

Johnson & Johnson CFO Joseph Wolk joins ‘Squawk Box' to discuss the company's quarterly earnings results that topped Wall Street's expectations.

Johnson & Johnson's stock JNJ, +0.05% fell 0.4% early Tuesday, after the healthcare company posted better-than-expected profit for the first quarter but sales that fell slightly short of expectations. The New Brunswick, N.J.

The company is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures during the Covid pandemic.

Johnson & Johnson reported a first-quarter profit above Wall Street estimates on Tuesday, helped by strong sales of its cancer drugs including top-selling blood cancer treatment Darzalex.